Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jun;25(6):659-668.
doi: 10.1111/1756-185X.14320. Epub 2022 Apr 6.

Anti-mitochondrial antibodies in Indian patients with idiopathic inflammatory myopathies

Prithvi Sanjeevkumar Gaur  1 , Naveen R  2 , Anamika Kumari Anuja  2 , Mantabya Kumar Singh  3 , Mohit Kumar Rai  2 , Rizwan Muhammed  2 , Ankit Kumar Sahu  4 , Vikas Agarwal  2 , Latika Gupta  2   5   6   7
Affiliations

Anti-mitochondrial antibodies in Indian patients with idiopathic inflammatory myopathies

Prithvi Sanjeevkumar Gaur et al. Int J Rheum Dis. 2022 Jun.

Abstract

Aims: Anti-mitochondrial antibodies (AMAs) are associated with distinct clinical phenotypes including cardiac and hepatic manifestations in idiopathic inflammatory myopathies (IIMs). This article studies the prevalence, clinical characteristics and outcomes of AMA in Indian patients with IIM.

Methods: Patients (97: 81 adult, 16 juvenile) clinically diagnosed with polymyositis or antibody-negative IIM were retrieved from the MyoCite bio-archive. They were tested for myositis-specific autoantibodies / myositis autoantibodies (MSAs/MAAs) using line immunoassay and antinuclear antibodies and AMAs using immunofluorescence assay (IFA). Patients were also screened for cardiac biomarkers (cardiac troponin I [c-TnI] and N terminal-pro brain natriuretic peptide [NT-pro-BNP] using immunometric immunoassay technique and enhanced chemiluminescence assay testing respectively) and hepatic manifestations using AMA testing. Results were formulated after carrying out analytical tests.

Results: Of the cohort, 5 adults (6.2%) (M:F 0:1) with a median age and disease duration of 37 years and 2 months respectively, tested AMA+ while the children tested negative. Dermatomyositis was the commonest phenotype, with amyopathic forms being common, often with MSA positivity. Cancer-associated myositis and polymyositis were also seen. AMA positivity is associated with Gottron's sign and calcinosis. Comparable levels of C-TnI and NT-pro-BNP and AMA testing in patients help to rule out subclinical cardiac and hepatic involvement respectively.

Conclusion: Anti-mitochondrial antibodies are rare (6.2%) in different subtypes of IIM in the Indian population, and often coexist with MSAs. Their negative association with cardiac and hepatic involvement and probable association with Gottron's sign and calcinosis merit further investigation and long-term follow-up to understand the entire spectrum of the disease.

Keywords: India; cardiac; dermatomyositis; mitochondria; myositis.

PubMed Disclaimer

References

REFERENCES

    1. McHugh NJ, Tansley SL. Autoantibodies in myositis. Nat Rev Rheumatol. 2018;14:290-302.
    1. Mackay IR. Primary biliary cirrhosis showing a high titer of autoantibody; report of a case. N Engl J Med. 1958;258:185-188.
    1. Ceribelli A, Isailovic N, De Santis M, Generali E, Satoh M, Selmi C. Detection of anti-mitochondrial antibodies by immunoprecipitation in patients with systemic sclerosis. J Immunol Methods. 2018;452:1-5.
    1. Becker Y, Loignon RC, Julien AS, et al. Anti-mitochondrial autoantibodies in systemic lupus erythematosus and their association with disease manifestations. Sci Rep. 2019;9:4530.
    1. Jin R, Wang XX, Wang LH, et al. Situation analysis of timing of first visit of anti-mitochondrial antibody-positive patients. Zhonghua Gan Zang Bing Za Zhi. 2019;27:643-647.